PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

Subjects who are newly diagnosed with symptomatic MM and who:

Have not received any prior systemic anti-myeloma therapy
Have measurable disease
And are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-006 for a subject <65 years old. There must be a comorbidity that prevents SCT for a subject <65 years old

Exclusion Criteria:

Subjects with non-secretory or oligo-secretory or free light-chain only myeloma
Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Active plasma cell leukemia
Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C